<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>senolytic drug on ScienceChronicle</title>
    <link>https://www.ScienceChronicle.org/en/tags/senolytic-drug/</link>
    <description>Recent content in senolytic drug on ScienceChronicle</description>
    <generator>Hugo -- gohugo.io</generator>
    <lastBuildDate>Thu, 18 May 2023 10:44:20 +0000</lastBuildDate><atom:link href="https://www.ScienceChronicle.org/en/tags/senolytic-drug/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>2nd Generation Senolytic Drug Derived from Navitoclax Shows Promising Results for Osteoarthritis and IPF</title>
      <link>https://www.ScienceChronicle.org/en/news/2nd-gen-senolytical-drug-for-osteoarthritis-ipf/</link>
      <pubDate>Thu, 18 May 2023 10:44:20 +0000</pubDate>
      
      <guid>https://www.ScienceChronicle.org/en/news/2nd-gen-senolytical-drug-for-osteoarthritis-ipf/</guid>
      <description>A 2nd generation senolytical drug derived from navitoclax has shown promising results in treating osteoarthritis and idiopathic pulmonary fibrosis (IPF), according to a new study conducted by researchers at the University of Birmingham in the UK. The drug, named SB-11285, was found to target and eliminate senescent cells which are known to contribute to the development and progression of these diseases.
Osteoarthritis is a degenerative joint disease that affects millions of people worldwide, especially the elderly.</description>
    </item>
    
  </channel>
</rss>
